<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">Abrupt withdrawal of RAAS inhibitors in high-risk patients, including those who have heart failure or have had myocardial infarction, may result in clinical instability and adverse health outcomes. Until further data are available, RAAS inhibitors should be continued in patients in otherwise stable condition who are at risk for, being evaluated for, or with COVID-19 [
 <xref ref-type="bibr" rid="CR56">56</xref>, 
 <xref ref-type="bibr" rid="CR57">57</xref>, 
 <xref ref-type="bibr" rid="CR60">60</xref>â€“
 <xref ref-type="bibr" rid="CR63">63</xref>].
</p>
